Data protection in the pharma sector: a many-headed hydra

24 April 2019

In an Expert View piece, Oliver Kidd, senior associate at Stevens & Bolton, provides an overview of an ever-more complex landscape.

As we approach May 25 and the first anniversary of the European Union’s (EU) General Data Protection Regulation (GDPR) coming into force, the sector should pause to review the current data protection landscape and the potential tripwires it poses for pharma businesses.

Understanding, and ensuring compliance with, data protection laws like the GDPR presents an ongoing challenge for the pharmaceutical industry, and one that is set to get more complex given this ever-changing landscape and new regulations coming down the track.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK